Cure My Disease

Don't miss your cure!

 Log in / Sign up

New group therapy aims to rewire depressed brains

NCT ID NCT07388004

Symptom relief Sponsor: Philipps University Marburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two new group therapies for adults with major depression. One therapy helps change rigid negative expectations, while the other boosts sensitivity to positive experiences. 150 participants will be randomly assigned to one of the therapies or a waiting list, and their symptoms will be tracked for 6 months. The goal is to see if targeting these specific brain processes leads to better and longer-lasting relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-80 years * Current diagnosis of major depressive disorder (MDD) according to DSM-5, confirmed by structured clinical interview (e.g., DIPS) * Hamilton Depression Rating Scale (HAMD-21) score ≥ 9 * Ability to attend group therapy sessions (2×/week for 5 weeks) * Ability to undergo MRI scanning (for participants in the fMRI component) Written informed consent Exclusion Criteria: * Current or lifetime diagnosis of bipolar disorder, psychotic disorder, or primary substance use disorder * High acute suicide risk requiring immediate intervention * Severe neurological disorder, brain injury, or contraindications for MRI (e.g., metal implants, claustrophobia) * Ongoing psychotherapy or initiation of a new antidepressant medication within the past 4 weeks * Insufficient German language proficiency to participate in therapy and complete study assessments * Cognitive impairment or other conditions interfering with informed consent or study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Philipps-University Marburg

    RECRUITING

    Marburg, Hesse, 35032, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.